New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 13, 2019 - Regeneron announced the FDA approval of Eylea (aflibercept), for the treatment of patients with diabetic retinopathy (DR).
Download PDF
Return to publications
